Trials / Unknown
UnknownNCT06144788
Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Therapeutic Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of JP-2266 in Patients With Type 2 Diabetes Mellitus
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 156 (estimated)
- Sponsor
- Jeil Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Therapeutic Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of JP-2266 in Patients with Type 2 Diabetes Mellitus
Detailed description
Evaluation of efficacy and safety when administered JP-2266 in type 2 diabetes patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGLT2 inhibitor | SGLT 1/2 dual inhibitor |
Timeline
- Start date
- 2023-11-01
- Primary completion
- 2024-03-01
- Completion
- 2025-04-01
- First posted
- 2023-11-22
- Last updated
- 2023-11-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06144788. Inclusion in this directory is not an endorsement.